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Lung cancer is the most frequent cause of cancer death among men
in all developed countries (Parkin et al, 1993) and, in most of the
United States, for women as well (Silverberg, 1998). In Europe,
lung cancer is the third leading cause of cancer death in women
(Black et al, 1997); in France, it is fourth (Black et al, 1997).
Small-cell lung cancer (SCLC) accounts for 20–25% of all lung
cancers (Carter and Eggleston, 1980; Janssen-Heijnen et al, 1995;
WHO, 1998). Its prognosis remains poor, with a median survival
time of about 12–16 months in LD and 7–11 months in ED (Albain
et al, 1990). 
Management of SCLC has changed substantially over time.
During the 1960s, surgery was found to be useless (Fox and
Scadding, 1973). As mediastinal irradiation became the most
frequently used treatment, disease was staged by the VALSG
(Veterans’ Administration Lung Study Group) two-category clas-
sification: the LD stage, in which the tumour and its connections
can be encompassed by a single radiotherapy port and the ED
stage, in which the tumour extends beyond the LD definition
(Zelen, 1973). Since 1969, chemotherapy became the cornerstone
of SCLC therapy (Green et al, 1969). The most frequently used
drug combinations were first CAV (cyclophosphamide, adri-
amycin and vincristine) (Livingston et al, 1978; Aisner et al, 1983)
and then etoposide with cisplatin, which is today the standard
treatment (Evans et al, 1985; Fukuoka et al, 1991; Roth et al,
1992). Two meta-analyses of 13 randomized trials comparing
chemotherapy alone with a combination of chemotherapy and
radiotherapy for LD patients concluded that combined treatment in
LD provided a small but definite survival benefit (Pignon et al,
1992; Warde and Payne, 1992). In ED, chemotherapy alone is the
usual treatment. Nonetheless, despite extreme initial sensitivity
to chemotherapy, most patients with SCLC relapse and become
resistant to chemotherapy (Giaccone et al, 1988). 
Improved survival rates over time have been reported in
analyses of series of patients included in consecutive therapeutic
trials over periods of several years (Spiegelman et al, 1989; Albain
et al, 1990; Chute et al, 1999). This improvement in survival over
time for patients in clinical trials may be due to many factors,
including stage migration (Feinstein et al, 1985) and selection and
lead-time biases (Antman et al, 1985; Quoix et al, 1986). The
possible role of improved therapy per se cannot therefore be
assessed in such studies. Few population-based studies have been
performed demonstrating, in the recent series, also improvement
in survival (Janssen-Heijnen et al, 1998a, 1998b; Engeland et al,
1998). We decided to conduct a retrospective study of the manage-
ment of all consecutively diagnosed patients with SCLC in the
Bas-Rhin (a French department, an administrative subdivision)
over a 14-year period to analyse their outcome and assess trends in
management and survival. 
PATIENTS AND METHODS 
Patients 
We reviewed the medical records of all 967 patients diagnosed
with SCLC between 1 January 1981 and 31 December 1994 in the
Bas-Rhin, which had between 900 000 and 1 000 000 inhabitants
during this period (INSEE, 1987). We obtained the list of patients
from the Bas-Rhin population-based cancer-registry. 
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Each chart included the following data: age, sex, date of
diagnosis, investigations performed for diagnosis and staging
purposes, disease extent according to the VALSG classification
(Zelen, 1973) and serum lactate dehydrogenase (LDH) levels. If
the chart did not report disease extent at diagnosis, we assigned the
stage retrospectively if at least two extra-thoratic procedures were
performed or, of course, when a metastatic site was found (the
patient was then classified as ED regardless of the number of
procedures). Otherwise, the stage was classified as undetermined. 
We recorded the first-line treatment received by the patient:
surgery, chemotherapy and/or mediastinal irradiation, prophylactic
cranial irradiation. The drugs used, the number of cycles adminis-
tered, and the total dose of irradiation delivered (Grays) were
noted. Participation in any clinical trial was also recorded. 
Survival was calculated from the date of pathological diagnosis
to the end point date which was 31 December 1998. 
Statistical methods 
Descriptive analysis 
All variables recorded were divided into five periods; four covered
3 years and the last period, only 2 (1993–1994). 
Differences between proportions were evaluated with the
Pearson χ 2 test or Fisher’s exact test (Armitage, 1971). 
Differences between the means of continuous variables were
evaluated with Student’s t-test or, if the comparison involved more
than two groups, one-way analysis of variance (Armitage, 1971). 
Correlation between continuous variables was assessed with the
correlation test (Schwartz, 1996). 
In the descriptive analysis, if both period effect and linear trend
were significant, only the latter’s P-value is indicated, because it
necessarily includes the period effect. When there was a period
effect without a significant linear trend, both significance values
are indicated. 
All continuous variables were categorized before analysis. Age
was categorized in three classes (less or equal to 55, from 56 to 70
and over 70). LDH dosage was categorized as normal or elevated. 
The BMDP package from the University of California, Los
Angeles, CA (BMDP, 1981) and STATXACT of Cytel Software
Corporation, Cambridge (STATXACT, 1995) were used to process
the data. 
Relative survival 
RELSURV software (2.0c) (Hédelin, 1995) was used to perform
univariate and multivariate analysis of survival with relative
survival rates. Considering relative survival enabled us to elimi-
nate the effect of improvement in general population survival
during the long period (14 years) covered by the study as well as
the effect of age-related mortality. 
Several pre-therapeutic and therapeutic variables were studied:
sex, age, disease extent, inclusion in a clinical trial, LDH, diag-
nosis period, chemotherapy and mediastinal irradiation. 
Combined chemotherapies were categorized in five groups:
cisplatin and etoposide solely, cisplatin with other drug(s) except
etoposide, etoposide with other drug(s) except cisplatin, neither
cisplatin nor etoposide, cisplatin and etoposide with other drug(s). 
RESULTS 
Descriptive analysis 
Of the 967 patients with SCLC listed in the cancer registry of
the Bas-Rhin during this period, 180 were excluded, for two
reasons: ineligibility due to wrong histological diagnosis (25
patients), absence of or insufficient medical records (155
patients). This study thus included 787 patients (83.4% of all
eligible patients). 
The sex ratio did not differ significantly between the 155
eligible patients excluded from this study and the 787 included:
133 (85.8%) and 696 (88.4%) men, respectively. The median
age of the excluded patients was 64, and of the included
patients, 63 (P = 0.05). Among the excluded patients, 67% were
diagnosed before 1988, compared with 46.8% of those included
(P = 10–5). 
Nineteen (2.4%) of the included patients were still alive at the
end point: 766 (97.3%) had died and 2 patients (0.3%) were lost to
follow-up. 
Table 1 summarizes the patients’ characteristics and the
temporal trends and Table 2 reports the procedures performed
(bronchofiberoscopy and imaging) over time. 
Finally, 248 patients (31.5%) were classified as LD at diagnosis
and 446 patients (56.7%) as ED. Inadequate testing prevented
Table 1 Characteristics of study population 
Period
1981–83 1984–86 1987–89 1990–92 1993–94
P
No. % No. % No. % No. % No. % 
Sex 
Male 127 90.7 149 87.1 148 90.8 168 87.5 104 86.0
0.60  Female 13 9.3 22 12.9 15 9.2 24 12.5 17 14.0 
Age (years) 
<=55 44 31.4 39 22.8 43 26.4 56 29.2 23 19.0 
56–70 64 45.7 84 49.1 83 50.9 98 51.0 60 49.6 0.19 
>70 32 22.9 48 28.1 37 22.7 38 19.8 38 31.4 
‘on’ prot 6 4.4 11 6.7 67 41.9 32 17.0 16 13.7 0.002 
Dis Ext* 
LD 43 39.4 47 33.3 49 33.3 66 36.1 43 37.7
0.81  ED 66 60.6 94 66.7 98 66.7 117 63.9 71 62.3 
Stage ND 31 22.1 30 17.5 16 9.8 9 4.7 7 5.8 10–5
*Proportion of defined stages; Dis Ext: disease extent; Stage ND: not determined; ‘on’ prot: ‘on’ protocol. 
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stage determination for 93 patients (11.8%). The proportion of
patients whose stage was undetermined decreased dramatically
over time (Table 1). 
The mean number of metastatic sites detected increased slightly
over time without any significant period effect (P = 0.09). There
was a significant correlation between the mean number of imaging
procedures and the mean number of sites detected with tumoral
involvement (Figure 1). 
Most of the patients were treated in the University Hospital of
Strasbourg (80.5%), but 17.2% were treated in community hospi-
tals and 2.3% in private clinics. There was a period effect for each
type of treatment: chemotherapy, mediastinal radiotherapy,
prophylactic cranial irradiation and surgery (Table 3). 
One hundred twenty-six patients (16%) did not receive any
chemotherapy. The median age of these patients was 73, compared
with 61 for those who did (P = 10–5). In the no-chemotherapy
group, there was no significant period effect for sex and age distri-
bution. The proportion of patients who had no chemotherapy
decreased significantly over time: from 23.6% during 1981–83 to
8.3% during 1993–94 (P = 10–5). 
There was a period effect for most drugs (Table 4). The use of
cisplatin and etoposide increased over time, and the use of
vincristine, lomustine and methotrexate decreased. Anthracyclines
were given to roughly 70% of patients throughout the entire
period. The mean number of cycles administered varied over time
(P = 10–4) without a linear trend (P = 0.19), from 5.1 in 1981–83 to
5.3 in 1993–94, with a peak of 6.2 in 1984–86. 
After the first period (1981–1983), the proportion of patients
receiving mediastinal irradiation decreased to about 24–25%. The
number of patients undergoing prophylactic cranial irradiation also
decreased substantially after the first period. Finally, the rate of
surgical resection remained minimal throughout the period. 
The proportion of patients included in clinical trials increased
irregularly over time, from 4.4% of all patients in 1981–83 to
13.7% in 1993–94, with a peak at 41.9% in 1987–89 (P =
0.002). All these patients were treated in the University
Hospital. 
Univariate analysis of survival 
Sixteen patients died before diagnosis and are excluded from
further analysis of survival. 
The overall median survival time increased over time, from 6.6
months in 1981–83 to 11.3 months in 1993–94 (P = 10–5). This
improvement was observed for both LD and ED patients (Figure
2): for LD patients, median survival increased from 9.2 months in
1981–83 to 14.0 months in 1993–94 (P = 0.002) and for ED
Table 2 Period effect for investigations performed 
Period
1981–83 1984–86 1987–89 1990–92 1993–94
P
No. % No. % No. % No. % No. % 
Fiberoscopy 136 97.8 164 95.9 160 98.2 186 97.4 117 96.7 0.75 
Thorax CT 7 5.1 44 27.2 92 56.4 160 85.6 110 91.7 10–5
Abdom US* 121 88.3 163 97.0 159 98.1 179 96.2 112 93.3 0.0007 
Adrenal CT 2 1.4 22 13.0 70 44.6 123 66.5 78 65.0 10–5
Brain CT 7 5.2 45 27.3 103 64.8 158 85.4 102 87.2 10–5
Bone scan 83 61.0 110 65.9 105 66.0 116 66.3 72 67.3 0.84 
BM Biopsy* 33 25.2 64 39.0 74 46.5 69 39.4 33 29.5 0.002 
*Linear trend not significant; Thorax CT: Thoracic CT- scan; Abdom US*: Abdominal ultrasound, P = 0.12 for linear trend; Adrenal CT: Adrenal CT-scan; 
Brain CT: Brain CT-scan; BM Biopsy*: Bone marrow biopsy, P = 0.40 for linear trend. 
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Figure 2 Period effect for median survival time. All patients: P = 10–5.LD: 
P = 0.002. ED: P = 10–5. (P = significance for linear trend) 
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patients from 3.5 months to 9.6 months (P = 10–5). This period
effect on survival was also observed and significant for patients
included in clinical trials and for those not included. 
The 1-year probability of survival increased from 24.2% in
1981–83 to 47.3% in 1993–94 for all patients (P = 0.002); the 
2-year probability of survival also increased from 7.9% in
1981–83 to 17.1% in 1993–94 (P = 0.03). For LD and ED
patients, respectively, the 1-year probability of survival
increased from 42.2% and 12.1% in 1981–83 to 69.5% and
39.2% in 1993–94 (P = 10–6 and 0.0003); the 2-year probability
from 21.2% and 1.4% in 1981–83 to 32.3% and 9.3% in 1993–94
(P = 10–6 and 0.006). 
One hundred and eight patients (14%) died within a month of
diagnosis: 51 (47.2%) received no treatment. The percentage of
early deaths did not vary over time. 
Multivariate analysis of survival 
Age, disease extent, inclusion in clinical trial, period,
chemotherapy and mediastinal irradiation were studied in a
forward stepwise fashion. LDH was omitted because of the
numerous missing values (44.8%). 
Two multivariate analyses were performed: 
  First, an analysis with the pre-therapeutic variables: disease
extent, inclusion in clinical trials, and period are indepen-
dent prognostic factors after adjustment for other factors
(Table 5). 
  The next analysis took into account not only pre-therapeutic
but also therapeutic factors (Table 6). Patients treated
with cisplatin plus etoposide plus other drug(s) did
better although not significantly. Mediastinal radiation
Table 4 Period effect for drugs used 
Period
1981–83 1984–86 1987–89 1990–92 1993–94
P
No. % No. % No. % No. % No. % 
Anthr 77 72.0 94 70.7 99 72.3 103 59.9 77 69.4 0.10 
VCR 85 79.4 83 62.4 43 31.4 21 12.2 21 18.9 10–5
Cyclifo 89 83.2 110 82.7 81 59.1 39 22.7 72 64.9 10–5
VP16 22 20.6 93 69.9 93 67.9 149 86.6 95 85.6 10–5
CDDP 13 12.1 76 57.1 48 35.0 126 73.3 85 76.6 10–5
Carbo* 0 0.0 1 0.8 18 13.1 2 1.2 4 3.6 10–5
Lomus 61 57.0 30 22.6 18 13.1 13 7.6 6 5.4 10–5
MTX 76 71.0 34 25.6 16 11.7 16 9.3 6 5.4 10–5
Other 21 19.6 10 7.5 9 6.6 7 4.1 3 2.7 10–5
* Linear trend not significant; Anthr = Anthracyclines = Doxorubicine or Epirubicine; Cyclifo = Cyclophosphamide or Ifosfamide; VCR = Vincristine; 
VP16 = Etoposide; CDDP = Cisplatin; Carbo* = Carboplatine, P = 0.27 for linear trend; Lomus = Lomustine; MTX = Methotrexate. 
Table 3 Period effect for therapy 
Period
1981–83 1984–86 1987–89 1990–92 1993–94
P
No. % No. % No. % No. % No. % 
CT 
All 107 76.4 133 77.8 138 84.7 172 89.6 111 91.7 10–5
LD 37 86.0 39 83.0 46 93.9 60 90.9 40 93.0 0.36 
ED 45 68.2 71 75.5 83 84.7 109 93.2 66 93.0 10–5
Med RT 
All 74 52.9 49 29.0 39 24.1 47 24.5 30 24.8 10–5
LD* 34 79.1 20 44.4 23 46.9 40 60.6 25 58.1 0.008 
ED 24 36.4 19 20.2 7 7.1 5 4.3 2 2.8 10–5
CT + Med RT 
All 58 41.4 34 19.9 32 19.6 43 22.4 29 24.0 0.006 
LD* 29 67.4 14 29.8 22 44.9 37 56.1 24 55.8 0.005 
ED 15 22.7 12 12.8 5 5.1 5 4.3 2 2.8 10–5
PCI 
All 25 17.9 8 4.7 5 3.1 3 1.6 6 5.0 10–5
LD 17 39.5 4 8.7 4 8.2 3 4.6 5 11.6 10–4
ED 8 12.1 3 3.2 1 1.0 0 0.0 0 0.0 10–5
Surgery 
All 4 2.9 7 4.1 8 4.9 1 0.5 1 0.8 0.05 
LD 2 4.7 4 8.7 6 12.5 0 0.0 0 0.0 0.05 
ED 1 1.5 2 2.1 0 0.0 1 0.9 1 1.4 0.70 
*Linear trend not significant; CT: Chemotherapy; Med RT: Mediastino-tumoral radiotherapy, for LD P = 0.34 for linear trend; CT + Med RT: Chemotherapy plus
mediastino-tumoral radiotherapy, for LD P = 0.75 for linear trend; PCI: Prophylactic cranial irradiation; For each treatment type, the number of LD + ED patients
is inferior to the number of all patients in which patients with not determined stage are also present. 
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had a significant favourable impact on survival in the LD
stage. 
DISCUSSION 
The distribution by sex, age and disease extent did not differ
significantly over time among the patients diagnosed with SCLC
in the Bas-Rhin from 1 January 1981 through 31 December 1994. 
Although the sex ratio in our study decreased from 9.8:1 during
the first period to 6.1:1 during the last period; this reduction was
not significant. In a population-based study of SCLC performed in
the Netherlands, the male/female ratio appeared to decrease from
14:1 in 1975–1979 to 4:1 in 1990–1994 (Janssen-Heijnen et al,
1998a). It is well known that the sex ratio is lower in Northern
Europe than in the countries of Southern Europe (Black et al,
1997). The absence of a period effect on the sex ratio in our study
is consistent with the late adoption of cigarette smoking by French
women (European Bureau For Action on Smoking Prevention,
1990). 
The median age in our series is 63, slightly lower than the 65
found in a Dutch population-based-analysis of SCLC patients
diagnosed between 1975 and 1994 (Janssen-Heijnen et al,
1998a). For patients in clinical trials in our study population
(16.7% of all patients), the median age was 59 years and the
proportion of patients older than 60 years was 45.5%.
Comparisons of age distribution in population-based series and
in series of patients included in clinical trials are not appropriate
because most trials have an upper age limit as an inclusion
criteria. The median age of a population-based series may also
reflect health policies and the country’s socio-economic status.
The percentage of elderly patients with SCLC may be under-
estimated if elderly patients with lung tumour masses do
not undergo diagnostic procedures at rates similar to younger
patients. 
In our population, 31.5% of the patients with known stage were
diagnosed with LD, and this proportion did not vary over time.
The proportion of patients whose disease stage was undetermined
decreased over time (from 22.1% to 5.8%). A survey of lung
cancer in the US also observed a dramatic decrease in the
percentage of unstaged cases from 1985 to 1995 (Fry et al, 1999).
In that study, as in ours, this change did not modify the distribution
of disease stages. 
The mean number of metastatic sites detected increased over
time, together with the number of procedures performed for
staging purposes. The increase in observed metastases probably
also reflects improvements in imaging quality. This is consistent
with other findings (Griffin et al, 1984; Spiegelman et al, 1989;
Dearing et al, 1990). 
We found that survival increased over time for the population
as a whole and for each category (LD, ED, included or not in
clinical trials). Retrospective studies of patients with SCLC in
consecutive clinical trials (Spiegelman et al, 1989; Albain et al,
1990; Chute et al, 1999) have also observed improved survival.
Many factors may account for the improvement in this group;
they include better staging because of more and better staging
procedures. The LD group may therefore be less ‘contaminated’
by small metastases undetectable with ‘older’ procedures; simul-
taneously the ED group may now include not only patients with
massive metastatic disease but also some patients with small
metastases detected with ‘new’ procedures (Feinstein et al,
1985). This stage migration, known as the ‘Will Rogers phenom-
enon’, results in an improved survival for LD and ED patients,
without improvement of the overall survival. The improved
survival of patients in consecutive clinical trials may therefore be
explained simply by the Will Rogers phenomenon (Spiegelman
et al, 1989; Albain et al, 1990; Chute et al, 1999) contrarily to our
study. 
In clinical trials, patient selection, through restrictive inclusion
criteria, may also affect the improved outcome of included patients
(Antman et al, 1985; Quoix et al, 1986). Again, this does not
explain the global improved survival in our series but may have
Table 5 Multivariate analysis for pre-therapeutic variables 
Variable Level Hazard ratio Cl 
Age (years) < = 55 1
55–70 1.27 0.92–1.74 
>70 1.51 0.96–2.40 
Disease extent* LD 1 
ED 2.04 1.68–2.47 
Inclusion in trial No 1 
Yes 0.60 0.47–0.76 
Period 1981–83 1 
1984–86 0.81 0.47–1.38 
1987–89 1.06 0.64–1.75 
1990–92 0.75 0.46–1.23 
1993–94 0.49 0.27–0.87 
CI: Confidence interval; * The 93 patients with undetermined stage are
excluded from the analysis. 
Table 6 Multivariate analysis for pre-therapeutic and therapeutic variables 
Variable Level Hazard ratio CI 
Age < 55 1 
56–70 1.19 0.9–1.59 
>70 1.08 0.68–1.71 
Disease extent7 LD 1 
ED 1.34 0.94–1.93 
Inclusion in trial No 1 
Yes 0.72 0.56–0.92 
Period 1981–83 1 
1984–86 0.69 0.33–1.42 
1987–89 0.89 0.43–1.86 
1990–92 0.67 0.28–1.57 
1993–94 0.49 0.22–1.09 
Chemotherapy Chemo 1 1 
Chemo 2 0.75 0.40–1.40 
Chemo 3 0.82 0.39–1.71 
Chemo 4 0.68 0.32–1.44 
Chemo 5 0.67 0.40–1.12 
Radiotherapy 
LD No 1 
Yes 0.52 0.31–0.89 
ED No 1 
Yes 0.85 0.57–1.25 
CI: Confidence interval; Chemo 1 = (Etoposide + Cisplatin) alone; 
Chemo 2 = Etoposide + other drug(s) (except Cisplatin); Chemo 3 = 
Cisplatin + other drug(s) (except Etoposide); Chemo 4 = neither Etoposide
nor Cisplatin; Chemo 5 = Etoposide + Cisplatin + other drug(s). 
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some role in explaining it for the 132 patients included in clinical
trials. 
Lead-time bias has been suggested as one possible explanation
of improved survival in clinical trials: it cannot be totally ruled out
in our study. The increase in the mean number of metastatic sites
detected over time may reflect a real absence of lead-time bias or
better detection of tumoral masses, but this better detection does
not necessarily preclude the possibility that in fact tumoral mass
might have diminished over time. 
Only a few studies have analysed survival in population-based
series of patients with SCLC. The US SEER population database
showed a prolongation in the survival of SCLC patients: median
survival time was 7.3 months in 1973–1974 and 9.3 months in
1993–1994 (Chute et al, 1999). The population database for the
Southeastern Netherlands also showed improved survival for
patients with SCLC from 1975–1979 (median survival: 5 months)
to 1990–1992 (median survival: 9 months) (Janssen-Heijnen et al,
1998a). 
Prognostic factors among patients with SCLC have been studied
primarily among series of patients included in clinical trials. The
prognostic role of age is quite controversial and there are some
real difficulties in assessing its prognostic role. First, elderly
patients are often excluded from clinical trials (Trumble et al,
1994). Second, the age cut-off varies significantly from study to
study: 65 in a Belgian study (Humblet et al, 1987), 70 in a Danish
study (Osterlind et al, 1986) and 75 in an English study (Souhami
et al, 1984). Third, elderly patients are less likely to be treated
aggressively than younger patients (Dajczman et al, 1996). It
appears that when the elderly receive the same type of treatment as
younger people do, age is not a prognostic factor (Sagman et al,
1991). The importance of appropriate treatment for the elderly is
also supported by our finding that age was not significant after
adjustment for treatment. 
The prognostic value of sex is also controversial. In most North
American series, prognosis is significantly more favourable
among women (Davis et al, 1985; Johnson et al, 1988; Spiegelman
et al, 1989; Wolf et al, 1991; Chute et al, 1997). Neither in our
study nor in a French series of 1280 patients included in four
consecutive trials did sex appear as a significant independent
factor. The sex-ratio in that series was 9:1 (Lebeau et al, 1995).
The low percentage of women with SCLC in France makes it diffi-
cult to ascertain whether sex has a prognostic role. 
Performance status (PS) of patients is a major prognostic factor
(Spiegelman et al, 1989; Albain et al, 1990; Rawson and Peto,
1990), especially for ED patients (Sagman et al, 1991). We could
not study its prognostic role, however, because it was systemati-
cally recorded only for patients in clinical trials. For them, PS was
an independent prognostic factor (data not shown).
Extent of disease is one of the strongest prognostic factors
(Spiegelman et al, 1989; Albain et al, 1990; Lassen et al, 1995;
Maestu et al, 1997), as our population-based series confirms.
Some authors report the prognostic importance of the number of
metastatic sites (Maurer and Pajak, 1981; Spiegelman et al, 1989;
Sagman et al, 1991). We did not study this because this number
depended on the number of imaging procedures. 
LDH is now recognized as an important prognostic factor
(Albain et al, 1990; Sagman et al, 1991; Maestu et al, 1997; Quoix
et al, 2000). We could not assess it in our multivariate analysis
because of the number of missing values. 
Patients included in clinical trials survived longer than patients
treated off-protocol. This reflects selection biases (Antman et al,
1985; Quoix et al, 1986). It is thus important to note that the results
obtained with patients included in clinical trials cannot be extrapo-
lated to the entire population of patients. 
At the same time as survival improved over time in our series of
patients, management of the disease also changed. The percentage
of patients undergoing chemotherapy increased from 76.4% in
1981 to 91.7% in 1994. Janssen-Heijnen et al report that improved
short-term survival in a population-based study was due to the
increased use of chemotherapy from the late 1970s onwards
(Janssen-Heijnen et al, 1998a). As in other countries, the combina-
tion of cisplatin and etoposide with or without other drug(s)
became the standard chemotherapy in our region. In a meta-
analysis of randomized trials of cisplatin-containing regimens
versus regimens without cisplatin, the former was associated with
a significant increase of survival of 2.6% at 6 months and 4.4% at
1 year (Pujol et al, 2000a). Paesmans et al showed that the admin-
istration of cisplatin and etoposide as components of a poly-
chemotherapy regimen, separately or together, improved survival
of SCLC patients (Paesmans et al, 1999). This review did not
differentiate between cisplatin-etoposide only and cisplatin-
etoposide associated with other drug(s). Combinations of
cisplatin, etoposide plus other drug(s) yielded the best results in
our study. This finding is consistent with the result of a French
multi-centre study that compared doublet cisplatin plus etoposide
to cisplatin plus etoposide plus cyclophosphamide plus epirubicin
(Pujol, 2000b). 
Mediastinal irradiation combined with chemotherapy is associ-
ated with better survival in patients with LD (Pignon et al, 1992;
Warde and Payne, 1992). This was confirmed in our series.
Moreover, during the second period there was a decrease of the
median survival time in LD which may be related to a dramatic
decrease of the percentage of LD patients treated with combina-
tion of chemotherapy plus mediastinal irradiation (29.8% versus at
less 45% during the other periods). It is noteworthy that part of the
dramatic decrease in the number of patients receiving mediastinal
irradiation after the first period is due to the fact that this treatment
was administered increasingly less often to ED patients. 
The subset of patients in our study who were treated by surgery
or received prophylactic cranial irradiation was too small to enable
us to analyse their survival. The decrease of the number of patients
receiving prophylactic cranial irradiation reflects probably the
evolution of the management of the disease restricting this treat-
ment to the patients responding completely to chemotherapy.
In conclusion, we observed in a French department population-
based series of SCLC patients a 4.7-month improvement in
median survival time, together with an 8% increase in the 2-year
probability of survival over a 14-year period which is encouraging.
The relative survival analysis confirmed the role of time in
improvement of survival paralleling the evolution of the manage-
ment of SCLC according to the ‘state of the art’. 
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